Pertussis vaccine greatly reduced the incidence of adverse effects compared to the earlier "whole-cell" pertussis vaccine, however immunity wanes faster after the acellular vaccine than the whole-cell vaccine. Between 10% and 50% of people given the whole-cell vaccines develop redness, swelling, soreness or tenderness at the injection site and/or fever, less than 1% experience febrile seizures or long periods of crying, and less than 1 out of every 1,000 to 2,000 people vaccinated have a hypotonic-hyporesponsive episode. The same reactions may occur after acellular vaccines, but are less common. Side effects with both types of vaccines, but especially the whole-cell vaccine, are
Peripheral artery disease )Trial. In 2011, pCMV-vegf165 was registered in Russia as the first-in-class gene therapy drug for treatment of PAD, including the advanced stage of critical limb ischemia. Peripheral artery disease Peripheral artery disease (PAD) is an abnormal narrowing of arteries other than those that supply the heart or brain. When narrowing occurs in the heart, it is called coronary artery disease, and in the brain, it is called cerebrovascular disease. Peripheral artery disease most commonly affects the legs, but other arteries may also be involved. The classic symptom is leg pain when walking which resolves with rest, known as intermittent claudication.